EBO2 (EBOO) for Longevity: What the Aging Research Does and Does Not Show

EBO2 (also called EBOO) is sold at longevity and biohacking clinics as a way to slow aging from the inside, usually alongside a mechanism story about controlled oxidative stress. This guide does something the sales pages do not: it reads the two aging papers that story rests on, says exactly what each one measured, follows the clinical trial those authors announced to see what became of it, sets the regulators’ wording on anti-aging claims next to it, and gives you the questions that separate a mechanism from a result. Nothing here says EBO2 does or does not affect aging; nothing published lets anyone say that.

The answer first

As of October 2, 2026, our research library holds no study, of EBO2 or of any other ozone therapy, that measured lifespan, a validated aging clock, or the rate of age-related disease in people. What exists is a mechanism literature about how ozone interacts with an antioxidant signalling pathway, almost all of it in cells, animals, or short-term blood markers. A mechanism is a reason to run a trial. It is not the trial.

What the two aging papers in our library actually say

Longevity marketing for ozone generally traces back to two kinds of paper. The first is the “ozone paradox” argument: prolonged ozone inhalation is harmful, while a single, carefully calibrated dose dissolved in blood outside the body is proposed to trigger a controlled burst of oxidative stress that the body answers with antioxidant and repair responses [5]. The second is the hormesis literature in the biology of aging. Both are in our library, and neither does the work the marketing asks of it.

Mehdi 2021 is a review of aging biology covering oxidative damage at the molecular, mitochondrial, cellular, and organ level, and discussing antioxidant supplementation, hormesis, and calorie restriction as anti-aging strategies [2]. Its abstract does not mention ozone, EBO2, or any ozone method anywhere. It is a legitimate source for the idea that a controlled stress can provoke a protective response. It is not a source for any claim about this procedure, and a clinic page that cites hormesis in general has not cited evidence about the treatment it is selling.

Scassellati 2020 is the paper that makes the ozone-specific argument. It proposes that ozone interacts with Nrf2, a transcription factor that switches on a cell’s own antioxidant genes, and pools biomarker studies to support that. Read closely, it describes its own standing plainly. Its stated aim is “a potential new strategy to delay neurodegeneration”, and its conclusion is that, “With the awareness that further studies are needed, this review reports substantial scientific evidence for building a rationale of using the O2-O3 therapy to delay aging processes and neurodegeneration” [1]. A rationale for use is not a demonstration of effect, and the authors say so.

Three details about its meta-analysis matter for anyone deciding what it proves.

A second pooled analysis in the same review, of the Nrf2, HO-1, and Hsp70 molecules (odds ratio 1.80), combines human, cell, and animal samples; the review attributes its heterogeneity, I² = 66%, to “different sources of samples (human, cell and animal models) and different methodology” [1]. That figure mixes laboratory and animal results with human ones, so it is not a human clinical finding either.

The review also carries a safety sentence that gets quoted on clinic pages: “The side effects are minimal; the World Federation of Ozone therapy (WFOT) estimates the incidence of complications at 0.0007%” [1]. That is a figure the review relays from an ozone-therapy trade body, not a rate the review measured, and no method for it is given. One of the review’s authors is affiliated with an oxygen-ozone therapy scientific society, which is a declared position worth weighing rather than a disqualification; the paper states that the authors declared no conflict of interest and that the work was supported by grants from the Italian Ministry of Health [1].

What happened to the trial that review announced

This is the part that is usually missing from pages citing the Nrf2 argument. In 2020 the review’s authors wrote that they had begun a randomized double-blind trial to test the therapy in a cognitive frailty cohort [1]. We followed it.

The trial is registered as NCT06071611, “Cognitive Frailty and Oxygen-ozone Therapy”, sponsored by the institute where the review’s first author works. The registry record lists an actual start in July 2019, an actual enrollment of 75 older people, randomized, double-blind, with three arms, and an actual completion date of November 17, 2023. When we read the record on October 2, 2026, it carried no posted results [4]. A protocol paper appeared in 2024 setting out the design and the endpoints, from frailty indices and memory tests to transcriptomic, proteomic, and metabolomic markers at 3, 9, and 15 months [3]. Searching the biomedical literature for the registration number, the authors, and the subject on the same date returned that protocol and a preprint of it, and no results paper.

One detail in the protocol deserves attention from anyone considering EBO2 specifically. The treatment arm was not blood filtration or anything resembling it. Participants received “a total amount of 150 cc of O2-O3 mixture at the concentration of 30 µg of O3 per cc of O2” by rectal insufflation, three sessions a week for five weeks, against pure oxygen and against air [3]. The flagship aging trial in this field used a route, a dose, and a schedule that have nothing in common with passing several litres of blood through an external circuit. Whatever it eventually reports will not be evidence about EBO2.

What clinics say, in the aggregate

Our directory records what each clinic states about EBO2 on its own website, with the quote and the page. As of October 4, 2026, of the 174 clinics whose EBO2 page we could read, 56 state a longevity or anti-aging benefit. That is one of the ten claim categories we record, and it sits on the same pages as claims about detoxification (the most common, at 151), energy or fatigue (133), infections, autoimmune conditions, and circulation. The block below shows every category with its count and the same denominator. We name no clinic in connection with a claim; the point is the pattern, which is that about a third of these clinics advertise an anti-aging benefit that has not been studied.

Two kinds of supporting material appear on some of those pages. One is the mechanism language above, cited to reviews rather than to trials. The other is before-and-after blood work, which is where the next section comes in.

Biomarker panels are a measurement, not an outcome

Some clinics point to inflammatory markers, blood counts, or a proprietary “biological age” score taken before and after a course. Four problems recur, and each one is a question you can ask.

• A marker is a surrogate. Blood pressure and LDL cholesterol earned their status as stand-ins for outcomes through decades of studies linking them to events. Most panels sold in longevity medicine have not been through that, so a movement in the number has no established meaning for how long or how well someone lives.
• Values move on their own. Hydration, a recent meal, sleep, a minor infection, and ordinary assay variation all shift results between two draws.
• Extreme first readings drift back toward the middle on a second measurement whatever happened in between, so a single before-and-after pair cannot distinguish that drift from a treatment effect.
• Many “biological age” scores are proprietary, meaning the company selling the test also defines the score, and the validation is not independent.

Reporting a favourable panel is a statement about the panel. A 2026 newspaper review of wellness and longevity treatments made the same general point about this category of clinic offering, noting that mechanisms demonstrated in laboratory or animal work routinely fail to translate into demonstrated human benefit [11].

What regulators have said about this kind of claim

No regulator we have found has ruled specifically on EBO2 for anti-aging. Several have ruled on the wider class of claim, in wording worth reading directly.

Underneath all of this sits the United States position on the gas itself. Ozone therapy is not FDA-approved for any medical use, and the federal device labeling rule states that ozone “is a toxic gas with no known useful medical application in specific, adjunctive, or preventive therapy” [6]. The phrase “preventive therapy” is the one that bears on a longevity sale, because prevention is exactly what an anti-aging course is sold as.

What a longevity course costs, and over how long

Longevity marketing frames EBO2 as maintenance rather than a short course for a problem, so the arithmetic that matters is annual, not per visit. The block below shows how many clinics in our directory publish a single-session price, the range, and the median, computed when the page is built. The cost of a plan is the session price times the cadence a clinic proposes, times the number of years in the plan. A 2026 report on the longevity clinic industry quoted a gerontologist’s assessment that “Public enthusiasm has outpaced scientific validation”, and observed that the interventions with the strongest evidence for extending healthy years, physical activity, nutrition, sleep, vaccination, and early detection of disease, tend to be the cheapest [12]. That is the comparison a multi-year protocol has to win.

Questions to ask a clinic selling this for aging

• Which published study tested this procedure with an aging outcome in people, and was that outcome lifespan, disease incidence, or a marker?
• Was the study you are citing done in people, in animals, or in cells, and was it this procedure or a different ozone method? The routes differ enormously, and results do not transfer between them.
• Which biological age test do you use, who validated it against long-term outcomes, and in what population?
• What is the recommended cadence, for how many years, and what is the total cost at your prices? The transparency block below shows how many clinics state a recommended course or a price on their page at all.
• What are the stopping rules? If the panel does not move, or moves the wrong way, what changes?
• Ask our questions to take to your doctor and check a quote against published prices with the price check tool.

What we could not verify

• Whether EBO2 has any effect, in either direction, on human aging. No study exists to answer it, and this guide makes no claim about it.
• Whether the completed frailty trial has results that have not yet been published, or whether they were reported somewhere our searches did not reach. We searched the trial registry and the biomedical literature by registration number, by author, and by subject on October 2, 2026, and found only the protocol.
• What the clinics in the longevity count mean by anti-aging in clinical terms. We recorded what their pages state; we did not ask them, and we did not evaluate the claims.
• The basis of the complication rate relayed in the 2020 review. The figure is attributed to a trade body, with no method given, and we could not trace it to a published dataset.
• Whether any regulator has considered EBO2 specifically as an anti-aging treatment. The records above concern ozone therapy and ozone devices more generally.
• How prices behave over a multi-year course. Our price data is a snapshot of published single-session prices and packages, not a record of what people were actually charged over years. The clinic directory shows what each clinic published and when we read it.

How this guide was made

This guide draws on 12 sources: five peer-reviewed papers and trial documents, five primary regulatory records, and two news reports used only for industry context. The claim counts come from our own directory of 177 US clinics, read between September 28, 2026 and October 4, 2026, with the denominator of 174 readable EBO2 pages stated wherever a count appears; price, course, and transparency figures in the blocks below are computed from that dataset at build time. The trial status was read from the public registry record and the biomedical literature on October 2, 2026. Drafting used AI tools. A human editor has not yet checked this guide claim by claim against its sources. No clinical reviewer has signed off on this page yet.